electroCore, Inc.ECOR
Key ratios
FCF / Sales
-25.8%2025
2024
-27.6%2023
-92.8%
Net margin
-40.0%TTM
2025
-43.6%2024
-47.2%2023
-117.5%
ROA
-55.0%TTM
2025
-42.0%2024
-41.6%2023
-59.0%
ROE
-478.7%TTM
2025
-478.7%2024
-158.6%2023
-153.6%
Revenue growth
27.2%2025
2024
57.1%2023
86.6%
Recent news
electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore Announces Third Quarter 2026 Financial Results
electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026
electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Air Force Lab Study Links Non-Invasive Vagus Nerve Stimulation to Faster Visual Skill Learning
electroCore to Present at Planet MicroCap Toronto 2026
Track ECOR in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer